Harnessing antifungal immunity in pursuit of a Staphylococcus aureus vaccine strategy

Area of Science:

• Immunology
• Vaccinology
• Microbiology

Background:

• Staphylococcus aureus (S. aureus) infections, including antibiotic-resistant Methicillin-Resistant S. aureus (MRSA), pose a significant global public health threat.
• Current vaccines against S. aureus have failed in clinical trials, highlighting the need for novel strategies.
• Immunocompromised individuals are particularly vulnerable to S. aureus and fungal infections, suggesting a potential link in immune responses.

Purpose of the Study:

• To investigate whether stimulating antifungal immunity could induce protective responses against S. aureus.
• To develop and test a novel vaccine strategy using fungal beta-glucan particles (GPs) loaded with S. aureus antigens.

Main Methods:

• Developed a vaccine (4X-SA-GP) by loading glucan particles with four S. aureus proteins (ClfA, IsdA, MntC, SdrE).
• Vaccinated mice with three doses of the 4X-SA-GP vaccine.
• Assessed protection in a systemic S. aureus infection model by measuring bacterial burden in spleen and kidneys.

Main Results:

• 4X-SA-GP vaccination significantly reduced bacterial burden in the spleen and kidneys of infected mice.
• The vaccine induced antigen-specific Th1 and Th17 CD4+ T cell responses, as well as antibody production.
• Protection was observed to be long-lasting.

Conclusions:

• Fungal beta-glucan particles loaded with S. aureus antigens can elicit protective immunity against S. aureus infection in mice.
• The GP vaccine system represents a potential novel platform for developing effective S. aureus vaccines.
• This approach may offer a new strategy to combat challenging S. aureus and MRSA infections.